Disclosure of Interests: Sahil Mahajan: None declared, Zhengfeng Yang: None declared, Elisabeth Mellins Grant/research support from: Novartis and GlaxoSmithKline., roberta faccio: None declared
DOI: 10.1136/annrheumdis-2019-eular.2846

FRIDAY, 14 JUNE 2019

Remission – the holy grail? Looking across diseases

OP0330

COMPARISON OF THE EFFECTS OF DORIS REMISSION AND LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) ON DISEASE OUTCOMES IN A MULTINATIONAL PROSPECTIVE STUDY

Vera Golder^{1,2}, Eric F. Morand^{1,2}, Rangi Kandane-Rathnayake¹, Molla Huq³, Worawit Louthrenoo⁴, Shue Fen Luo⁵, Yeong-Jian Wu⁵, Aisha Lateef⁶, Sargunan Sockalingam⁷, Sandra Navarra⁸, Leonid Zamora⁸, Laniyati Hamijoyo⁹, Yasuhiro Katsumata¹⁰, Masayoshi Harigai¹⁰, Madelynn Chan¹¹, Sean O'Neill¹², Fiona Goldblatt¹³, Chak Sing Lau¹⁴, Li Zhanguo¹⁵, Alberta Hoi^{1,2}, Mandana Nikpour³, Asia Pacific Lupus Collaboration. ¹Monash University, Clayton Campus, Clayton, Australia; ²Monash Medical Centre, Clayton, Australia; ³University of Melbourne, Parkville, Australia; ⁴Chiang Mai University, Chiang Mai, Thailand; ⁵Chang Gung Memorial Hospital, Guishan, Taiwan, Republic of China; ⁶National University Hospital, Singapore, Singapore; ⁷University of Malaya, Kuala Lumpur, Malaysia; ⁸University of Santo Tomas Hospital, Manila, Philippines; ⁹Padjadjaran University, Bandung, Indonesia; ¹⁰Tokyo Women's Medical University, Shinjuku, Japan; ¹¹Tan Tock Seng Hospital, Singapore, Singapore; ¹²Liverpool Hospital School, Liverpool, Australia; ¹³West Terrace, Adelaide, Australia; ¹⁴University of Hong Kong, Hong Kong, Hong Kong (SAR); ¹⁵Peking University, Beijing, China

Background: The Definitions of Remission in SLE (DORIS) group has proposed multiple definitions of remission, but these are infrequently attained and have not been prospectively evaluated in relation to protection from damage accrual. In contrast, the Lupus Low Disease Activity State (LLDAS) is more attainable, and has been shown to be associated with improved patient outcomes.

Objectives: To compare the attainability, and association with outcomes, of LLDAS and remission in a prospective multicentre study.

Methods: A prospective multinational cohort study was undertaken in 13 centres between 2013-2017. Time dependent Cox proportional hazards models were used to compare LLDAS and DORIS definitions of remission in terms of impact on disease flares and damage accrual.

Results: 1735 SLE patients were recruited, and followed for (mean±SD) 2.2±0.9 years, totalling 12,717 visits. LLDAS was achieved in 47.2% of observed visits. In contrast, remission was achieved in 1.1%-15.4% of visits depending on the stringency of remission definition. LLDAS attainment at any visit was associated with significantly reduced subsequent flare (HR 0.65, 95%CI 0.56-0.75, p<0.001) and damage accrual (HR 0.59, 95%CI 0.45-0.76, p<0.001). In contrast, only the least stringent remission definition was associated with reduced damage accrual (HR 0.58, 95%CI 0.39-0.88, p 0.01). Only remission definitions including serological remission were significantly associated with reduction in subsequent flares. Patients who spent ≥50% of their observed time in LLDAS had reduction in damage accrual (HR 0.54, 95% CI 0.42-0.70, p<0.001) compared to patients with <50% of observed time in LLDAS; again, only the least stringent remission definition, or the related definition excluding serology, were associated with reduced damage (HR 0.59, 95% CI 0.42-0.83, p 0.003; HR 0.69, 95% CI 0.48-0.99, p 0.05, respectively).

Conclusion: LLDAS was more attainable than any remission definition, whilst still conferring significant reduction in flares and damage accrual. Only the least stringent remission definitions could be shown to be associated with significantly lower damage accrual, likely reflecting a low frequency of remission attainment overall. LLDAS is a valid treatment target for SLE and is more achievable than remission.

Disclosure of Interests: Vera Golder: None declared, Eric F. Morand Grant/research support from: AstraZeneca, Bristol Myers Squibb, Janssen, Merck Serono, and UCB, Consultant for: AstraZeneca, Eli Lilly, Janssen, and Merck Serono, Speakers bureau: AstraZeneca, Rangi Kandane-Rathnayake: None declared, Molla Huq: None declared, Worawit Louthrenoo: None declared, Shue Fen Luo: None declared, Yeong-Jian Wu: None declared, Aisha Lateef: None declared, Sargunan Sockalingam: None declared, Sandra Navarra: None declared, Leonid Zamora: None declared, Laniyati Hamijoyo: None declared, Yasuhiro Katsumata: None declared, masayoshi harigai Grant/research support from: Tokyo Women's Medical University (TWMU) has received unrestricted research grants for Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases from Ayumi Pharmaceutical Co. Ltd., Bristol Meyers Squibb, Chugai Pharmaceutical Co. Ltd., Nippon Kayaku Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Corp., and with which TWMU paid the salary of MH. MH has also received research grants from AbbVie Japan

GK, Eisai Co. Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Madelynn Chan: None declared, Sean O'Neill: None declared, Fiona Goldblatt: None declared, Chak Sing Lau: None declared, Zhanguo Li: None declared, Alberta Hoi Grant/research support from: GSK, AstraZeneca, UCB and Merck Serono, Consultant for: Janssen Steering Committee, Speakers bureau: Novartis, Mandana Nikpour: None declared
DOI: 10.1136/annrheumdis-2019-eular.5136

OP0331

MAGNETIC RESONANCE IMAGING TENOSYNOVITIS AND OSTEITIS ARE INDEPENDENT PREDICTORS OF RADIOGRAPHIC AND MRI DAMAGE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS IN CLINICAL REMISSION

Signe Møller-Bisgaard^{1,2}, Kim Hørslev-Petersen³, Bo Ejbjerg^{2,3}, Merete L. Hetland¹, Lykke Ørnbjerg¹, Daniel Glinatsi¹, Jakob Møllenbach Møller³, Mikael Boesen³, Kristian Stengaard-Pedersen³, Ole Madsen³, Bente Jensen³, Jan Villadsen³, Ellen Margrethe Hauge³, Philip Bennett³, Oliver Hendricks³, Karsten Asmussen³, Marcin Kowalski³, Hanne Merete Lindegaard³, Henning Bliddal³, Niels Steen Krogh⁴, Torkell Ellingsen³, Agnete Nielsen³, Lone Balding³, Anne Grethe Jurik³, Henrik Thomsen³, Mikkel Østergaard¹. ¹Rigshospitalet, Glostrup, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Glostrup, Denmark; ²Slagelse Hospital, Slagelse, Denmark; ³Rheumatology and Radiology departments at hospitals at Zealand, Jutland and Funen, Copenhagen, Slagelse, Aarhus, Silkeborg, Odense, Hjørring and Graasten, Denmark; ⁴ZiteLab, Copenhagen, Denmark

Background: Progression of structural joint damage occurs in 20-30 % of patients with rheumatoid arthritis (RA) in clinical remission¹. Magnetic resonance imaging (MRI)-detected synovitis and in particular osteitis/bone marrow edema (BME) are known predictors of structural progression in both active RA and in remission, but the predictive value of adding MRI tenosynovitis assessment as potential predictor in patients in clinical remission has not been investigated.

Objectives: To investigate the predictive value of baseline MRI inflammatory and damage parameters on 2 year MRI and X-ray damage progression in an RA cohort in clinical remission, following MRI and conventional treat-to-target (T2T) strategies.

Methods: 200 RA patients in clinical remission (DAS28-CRP<3.2 and no swollen joints) on conventional DMARDs, included in the randomized IMAGINE-RA trial² (conventional DAS28 + MRI-guided T2T strategy targeting absence of BME vs conventional DAS28 guided T2T strategy) had baseline and 2 years contrast-enhanced MRIs of the dominant wrist and 2nd-5th MCP joints and X-rays of hands and feet performed, which were evaluated with known chronology by two experienced readers according to the OMERACT RAMRIS scoring system and Sharp/van der Heijde method, respectively.

The following potentially predictive baseline variables: MRI BME, synovitis, tenosynovitis, MRI and X-ray erosion and joint space narrowing (JSN) score, CRP, DAS28, smoking status, gender, age and patient group were tested in univariate logistic regression analyses with 2-year progression in MRI combined damage score, Total Sharp Score (TSS), and MRI and X-ray JSN and erosion scores as dependent variables. Variables with p<0.1, age, gender and patient group were included in multivariable logistic regression analyses with backward selection.

Results: Based on univariate analyses MRI BME, synovitis, tenosynovitis, x-ray erosion and JSN, gender and age were included in subsequent multivariable analyses. Independent MRI predictors of structural progression were BME (MRI progression) and tenosynovitis (MRI and X-ray progression), see table.

		Dependent variables, progression ≥1 from baseline to month 24 ^a				
		MRI			X-ray	
		MRI Erosion	MRI JSN	MRI combined damage score	X-ray Erosion	X-ray JSN
Explanatory variables	MRI BME	1.13 (1.06-1.21) p<0.001	1.18 (1.08-1.29) p<0.001	1.22 (1.12-1.33) p<0.001		
	MRI Tenosynovitis	1.13 (1.03-1.25) p=0.01	1.21 (1.04-1.40) p=0.01	1.13 (1.02-1.26) p=0.02		1.10 (1.00-1.21) p=0.04
Age					0.96 (0.93-0.99) p=0.007	

^a: Odds Ratio (95% confidence interval; CI) p-value;

MRI combined damage score: sum score of MRI erosion and JSN scores.